NCT01458561终止3 期
An Investigational Plan Evaluating the Operative Management of Parenchymal Bleeding By Means of an Adjunctive Application of BioFoam Surgical Matrix in Liver Surgery
适应症
试验速览
- 阶段
- 3 期
- 状态
- 终止
- 入组人数
- 1
- 试验地点
- 4
- 主要终点
- Time to Achieve Intraoperative Hemostasis Following Open Liver Resection Surgery in Subjects Receiving an Application of BioFoam or a Standard Topical Hemostatic Agent
研究概览
简要总结
This is a prospective, multicenter, randomized, controlled investigation. Subjects in which bleeding from the exposed parenchymal surface is observed intraoperatively following the ligature of vessels visible with the unaided eye will be randomized to an adjunctive application of BioFoam or a standard topical hemostatic agent (Gelfoam with thrombin, in the form of Gelfoam Plus) to the entire exposed parenchymal surface. Following primary treatment of the exposed parenchymal surface as prescribed by the randomization scheme, treatment sites will be visually evaluated for the continued presence of bleeding. The overall objective of this investigation is to collect clinical data concerning the safety and effectiveness of BioFoam used as an adjunct to conservative measures of achieving hemostasis, such as manual pressure, cautery, and ligation, for intraoperative capillary, arteriolar, and venular bleeding (5 second stack of 5 gauze surface "Bleeding Score" = 1b or 2, score to be validated) on newly resected liver parenchyma in hemodynamically stable (American College of Surgeons' Advanced Trauma Life Support Class I Hemorrhage) and non-coagulopathic patients in the open treatment of exposed liver parenchyma versus a standard topical hemostatic agent, Gelfoam Plus. It is not intended for traumatic liver injury. The investigation will be conducted at a maximum of three investigational sites.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject is undergoing an elective liver resection procedure that requires treatment of the exposed parenchymal surface due to the intraoperative presence of blood following ligature of vessels visible with the unaided eye;
- •Subject has adequate hepatic function as indicated by a Model for End-Stage Liver Disease (MELD) score of <10 at ≤30 days and at ≤7 days prior to surgery;
- •Subject has adequate hemostatic function identified as an international normalized ratio (INR), platelet count, and activated clotting time within the central laboratory's normal reference range;
- •Subject or an authorized legal representative is willing and able to give prior written informed consent for investigation participation; and
- •Subject is ≥ 18 years of age.
- •Preoperative
排除标准
- •Subject with known or suspected sensitivity to products of bovine origin
- •Subject with known or suspected sensitivity to glutaraldehyde
- •Subject with active infection (either systemic or in the treatment region) or hepatic cysts due to parasitic disease and/or abscesses due to bacterial and/or amebic disease;
- •Subject with abnormal calcium metabolism identified as values for ionized calcium and serum calcium corrected for serum albumin that are outside of the central laboratory's normal reference range;
- •Subject with abnormal renal status identified as an estimated glomerular filtration rate (eGFR), blood urea nitrogen (BUN), serum creatinine, sodium, chloride, potassium, and/or bicarbonate values that are outside of the central laboratory's normal reference range;
- •Subject with hyperparathyroidism identified as an intact parathyroid hormone level >72 pg/mL, serum calcium >10.6 mg/dL, and phosphate <2.4 mg/dL, and, for secondary or tertiary hyperparathyroidism only, alkaline phosphatase >147 U/L
- •Subject with a pancreatic amylase and/or lipase value outside of the central laboratory's normal reference range;
- •Subject with blunt and/or penetrating liver trauma;
- •Subject diagnosed with any coagulation disorder;
- •Subject whose life-expectancy is less than that required for the prescribed follow-up duration;
- •Subject who has been treated with an investigational product and has not completed the entire follow-up period for that investigational product;
- •Subject with any surgical implant that would interfere with necessary follow-up imaging;
- •Subject who is pregnant (as confirmed by a urine pregnancy test), planning on becoming pregnant during the follow-up period, or actively breast-feeding;
- •Subject who is undergoing concomitant procedures other than (1) cholecystectomy, (2) umbilical hernia repair, or (3) uncomplicated colon resection (i.e., no significant spillage);
- •Subject who is immunocompromised;
- •Subject with an American Society of Anesthesiologist (ASA) Score >2
- •Subject with a MELD score of ≥10 at ≤30 days or at ≤7 days prior to surgery;
- •Subject diagnosed with an autoimmune disease; and
- •Subject in whom the surgeon intends to use adhesion prevention products.
- •Subject who is returning to the operating room (OR) to address a complication associated with a liver resection, including but not limited to hematoma evacuation and biliary leak.
- •Intraoperative Inclusion Criterion:
- •Subject in whom bleeding (assignment of a "Bleeding Score" of 1 or 2) from the exposed parenchymal surface after ligature of vessels visible with the unaided eye and removal of any clamps used for hemostasis is observed
- •Intraoperative Exclusion Criterion:
- •Subject in whom any major intraoperative bleeding incidences during the resection procedure occurred (i.e., subject with assignment of an American College of Surgeons Advanced Trauma Life Support Hemorrhage Class of II, III, or IV Hemorrhage)
结局指标
主要结局
Time to Achieve Intraoperative Hemostasis Following Open Liver Resection Surgery in Subjects Receiving an Application of BioFoam or a Standard Topical Hemostatic Agent
时间窗: 3 minutes following a single application of the prescribed hemostatic agent
Number of subjects achieving intraoperative hemostasis (y/n) at 3 minutes following a single application of the prescribed hemostatic agent
次要结局
- Amount of Postoperative Fluid Loss(Time from drain insertion to drain removal (where applicable), average 24-72 hours postoperatively)
- Eval. for Presence of Device by MRI w/ & w/Out Contrast, & Diagnose/Eval. Abdominal Fluid Collection/Biliary Leak, Residual Scarring, Hepatic Regeneration, & Assess for Emergence of Primary/Recurrent Malignancy by MRI w/ or w/Out Contrast as Appropriate(Within 48 hours postoperatively, up to 48 hours prior to hospital discharge (avg. 5-7 days postoperatively), and 30 days, 3 months, 6 months, 9 months, 1 year, and 2 years postoperatively)
- Time to Hemostasis(1, 3, 5, 7, and 10 minutes following application of prescribed hemostatic agent)
- Achievement of Immediate Hemostasis(1 minute after application of prescribed hemostatic agent)
- Intraoperative Blood Loss(Time from initial application to confirmed achievement of hemostasis (eval. up to 10 minutes following application of hemostatic agent))
- Amount of Postoperative Bilious Drainage(Time from drain insertion to drain removal (where applicable), average 24-72 hours postoperatively)
- Amount of Intraoperative Blood Products Administered(Intraoperatively (throughout procedure, from initial skin cut to final wound closure, average 4-5 hours duration))
- Duration of Drainage(Time between drain insertion and last recorded emptying time during hospitalization (where applicable), average 24-72 hours postoperatively)
- Core Body Temperature(At the time of test or control article application (expected average 3-4 hours from skin cut))
- Total Hospitalization Time(Hospital admission (day of surgery) until hospital discharge (average 5-7 days))
- Subjects Requiring Additional Hospitalization/Surgical Intervention(Any hospitalization/surgical intervention following final wound closure through 2 year follow-up visit (average 2 yr duration))
- Subject Laboratory Evaluations(Preoperatively through final 2 year follow-up)
- Total Time of Operative Procedure(Skin cut to skin closure (average 4-5 hour duration))
- Number of Subjects Requiring Reoperation Due to Bleeding and/or Biliary Leakage (Reoperation Required? y/n)(After final wound closure through 2 year follow-up visit (average 2 yr duration))
- Evaluation of Anti-Bovine Serum Albumin (Anti-BSA) Antibody Titers(Preoperatively (up to 30 days before surgery), immediately post-application of hemostatic agent (within minutes), within 48 hrs postoperatively, up to 48 hrs before hospital discharge, at 7-10 days, 30 days, 3 mos, 6 mos, 9 mos, 1 yr, and 2 yr postop)
- Number of Procedure Complications and/or Adverse Events(Through final follow-up (2 years postoperatively))
研究者
研究点 (4)
Loading locations...
相似试验
已完成
不适用
Bleeding Incidence in VWD Patients Undergoing On-Demand TreatmentVon Willebrand DiseasesNCT04053699Octapharma56
招募中
不适用
Coronary Non-slip Balloon Catheter in Patients With Coronary Artery Stenosis(CREST)Coronary Artery StenosisNCT05606367Shanghai MicroPort Rhythm MedTech Co., Ltd.200
已完成
不适用
Bioresorbable Glass Fiber Matrix in the Treatment of Diabetic Foot UlcersUlcer FootDiabetic FootDiabetic Foot UlcerNCT06403605ETS Wound Care, LLC148
已完成
3 期
ArterX Surgical Sealant, A Randomized Prospective Multicenter TrialVascular DiseaseNCT00759681Tenaxis Medical, Inc.217
已完成
不适用
Post Market Study for an Adhesion Barrier Following Laparoscopic MyomectomyFibroidMyomaLeiomyomaNCT00891657Integra LifeSciences Corporation15